Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomocysteinemia- a rare case report.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2022-01-26 DOI:10.2174/1871529X22666220126122458

Arjun Kachhwaha, Amit Kumar Rohila, Swapnil Tripathi, Durga Shankar Meena, Satyendra Khichar, Deepak Kumar

{"title":"Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomocysteinemia- a rare case report.","authors":"Arjun Kachhwaha, Amit Kumar Rohila, Swapnil Tripathi, Durga Shankar Meena, Satyendra Khichar, Deepak Kumar","doi":"10.2174/1871529X22666220126122458","DOIUrl":null,"url":null,"abstract":"Background: Patients with hemophilia have a hypocoagulable state and less chances of thrombus formation. Therefore, expected to have a lower cardiovascular mortality than the general population. The lower cardiovascular mortality can be explained by less chances of thrombus formation due to hypocoagulability.Case presentation: Here we present a case of a 42-year-old male patient presented with severe chest pain radiating to back for 4 days. ECG was suggestive of recent acute anteroseptal myocardial infarction. There was a history of receiving intravenous recombinant factor VIII, 1 hour prior to the onset of chest pain for knee joint swelling. The occurrence of acute coronary syndromes in patients with hemophilia A is uncommon and rarely reported.Conclusion: Here we report a patient of severe hemophilia A who developed acute myocardial infarction after administration of recombinant factor VIII.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X22666220126122458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with hemophilia have a hypocoagulable state and less chances of thrombus formation. Therefore, expected to have a lower cardiovascular mortality than the general population. The lower cardiovascular mortality can be explained by less chances of thrombus formation due to hypocoagulability.

Case presentation: Here we present a case of a 42-year-old male patient presented with severe chest pain radiating to back for 4 days. ECG was suggestive of recent acute anteroseptal myocardial infarction. There was a history of receiving intravenous recombinant factor VIII, 1 hour prior to the onset of chest pain for knee joint swelling. The occurrence of acute coronary syndromes in patients with hemophilia A is uncommon and rarely reported.

Conclusion: Here we report a patient of severe hemophilia A who developed acute myocardial infarction after administration of recombinant factor VIII.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伴有艾滋病毒和高同型半胱氨酸血症的 A 型血友病患者急性心肌梗死--一例罕见病例报告。

背景：血友病患者的凝血功能低下，血栓形成的机会较少。因此，与普通人相比，血友病患者的心血管死亡率较低。心血管疾病死亡率较低的原因是低凝状态导致血栓形成的机会较少：我们在此介绍一例 42 岁男性患者的病例，他因剧烈胸痛并向背部放射 4 天而就诊。心电图提示近期急性前壁心肌梗死。患者在胸痛发作前 1 小时曾因膝关节肿胀接受过静脉注射重组因子 VIII。A 型血友病患者发生急性冠状动脉综合征的情况并不常见，也鲜有报道：在此，我们报告了一名严重的 A 型血友病患者在使用重组 VIII 因子后发生急性心肌梗死的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.